Skip to main content

Table 2 RH of clinical progression from fitting a Cox regression model

From: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV

  Crude and adjusted relative hazards of new AIDS or non-AIDS Severe Events (SNAEs) or death in total population
Crude RH
(95% CI)
p-value Adjusteda RH
(95% CI)
p-value Adjustedb RH
(95% CI)
p-value
(a) Biomarkers fitted as categorical variables
LPS, pg/ml
   < =250.8 1.0   1.0   1.0  
   > 250.8 0.85 (0.53, 1.36) 0.495 0.76 (0.46, 1.26) 0.292 0.88 (0.52, 1.49) 0.643
  not measured 1.09 (0.72, 1.65) 0.681 1.11 (0.72, 1.73) 0.631 1.22 (0.77, 1.92) 0.400
sCD14, ug/ml
   < =2.83 1.0   1.0   1.0  
   > 2.83 1.10 (0.77, 1.58) 0.586 0.95 (0.65, 1.39) 0.805 0.88 (0.59, 1.29) 0.504
  not measured 1.26 (0.40, 4.03) 0.695 0.87 (0.26, 2.86) 0.819 1.44 (0.41, 5.02) 0.570
EndoCAb, MMU/ml
   < =36.5 1.0   1.0   1.0  
   > 36.5 0.75 (0.52, 1.06) 0.107 0.82 (0.56, 1.19) 0.296 0.84 (0.57, 1.24) 0.378
  not measured 0.22 (0.03, 1.56) 0.129 0.19 (0.03, 1.38) 0.100 0.18 (0.02, 1.40) 0.100
hs-CRP, mg/L
   < =1.51 1.0   1.0   1.0  
   > 1.51 1.52 (1.01, 2.29) 0.044 1.47 (0.96, 2.26) 0.077 1.54 (0.99, 2.39) 0.056
  not measured 1.19 (0.74, 1.93) 0.478 1.26 (0.76, 2.07) 0.369 1.28 (0.77, 2.13) 0.345
(b) Biomarkers fitted as continuous variables in the loge scale
LPS, pg/ml
  per loge higher 0.99 (0.73, 1.35) 0.971 0.94 (0.68, 1.31) 0.729 0.72 (0.46, 1.12) 0.147
sCD14, ug/ml
  per loge higher 1.17 (0.84, 1.63) 0.342 0.95 (0.64, 1.40) 0.798 0.79 (0.41, 1.51) 0.471
EndoCAb, MMU/ml
  per loge higher 0.87 (0.70, 1.07) 0.195 0.94 (0.75, 1.17) 0.567 1.03 (0.70, 1.52) 0.874
hs-CRP, mg/L
  per loge higher 1.12 (0.99, 1.27) 0.065 1.07 (0.94, 1.21) 0.334 1.06 (0.89, 1.25) 0.539
  1. Note: SNAEs: cardiac decompensation, chronic renal insufficiency, liver diseases, myocardial infarction, malignancies, pneumonia, renal diseases and septic infections a All models (a separate one for each biomarker) adjusted for age, CD4, VL, HCV/HBV, years of cART, duration of HIV infection at starting cART, type of cART started bFurther mutually adjusted for all biomarkers